Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | HTR1D | P28221 | 4/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033870 | 0.90 | NISCH (0.69) | NISCHMAOAMAOBHTR1DTAAR1 | |
| SCHEMBL11884449 | 0.83 | NISCH (0.80) | NISCHMAOAMAOBTAAR1TSHR | |
| SCHEMBL5350249 | 0.80 | NISCH (0.56) | NISCHMAOAMAOBHTR1DTAAR1 | |
| SCHEMBL4041332 | 0.80 | MAOB (0.56) | NISCHMAOAMAOBHTR1DTAAR1 | |
| SCHEMBL10846005 | 0.78 | MAOA (0.57) | NISCHMAOAMAOBHTR1DTAAR1 | |
| SCHEMBL4032771 | 0.74 | MAOB (0.49) | NISCHMAOAMAOBHTR1DTAAR1 | |
| SCHEMBL5326165 | 0.74 | TAAR1 (0.68) | NISCHMAOAMAOBHTR1DTAAR1 | |
| SCHEMBL7010978 | 0.72 | MAOA (0.46) | NISCHMAOAMAOBGAA | |
| SCHEMBL14029045 | 0.72 | NOS3 (0.44) | NISCHMAOAMAOBHTR1DTAAR1 | |
| SCHEMBL14029058 | 0.72 | NOS3 (0.44) | NISCHMAOAMAOBHTR1DTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635821-B1 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | claimed |
| EP-1635821-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | claimed |
| WO-2004099155-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1635821-B1 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | ELAN PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
| EP-1635821-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Elan Pharmaceuticals, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2004099155-A2 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL) AMIDE DERIVATES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123531-A1 | 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases | BDKRB1, BDKRB2, LTB4R | NISCH 371/4885MAOA 1542/4885MAOB 615/4885 |
| US-20050032868-A1 | Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | NISCH 153/4885MAOA 1581/4885MAOB 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.